Twist Bioscience Corporation (TWST) Tops Q2 EPS by 4c, Revenues Beat; FY19 Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Twist Bioscience Reports Second Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress
April 30, 2019 4:05 PM EDT-- Reports Record Revenue of $13.6 Million for Second Quarter of Fiscal 2019 --
-- Increasing Orders Show Sequential Growth in Synthetic Biology and Next-Generation Sequencing Products --
-- Updates Fiscal 2019 Financial Guidance --
SAN FRANCISCO--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2019 ended March 31, 2019.
We continue to post strong topline growth as we... More
